Results 101 to 110 of about 12,196 (247)

Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: Implications in Parkinson’s disease

Communications Biology
Parkinson’s disease is managed using levodopa; however, as Parkinson’s disease progresses, patients require increased doses of levodopa, which can cause undesirable side effects. Additionally, the oral bioavailability of levodopa decreases in Parkinson’s
Gang Cheng, Micael Hardy, Cecilia J. Hillard, Jimmy B. Feix, Balaraman Kalyanaraman   +4 more
doaj   +1 more source

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats

Drug Design, Development and Therapy, 2012
Xinxin Yang,1,* Yinghui Chen,2,* Xiaoyun Hong,3 Na Wu,1 Lu Song,1 Weien Yuan,3 Zhenguo Liu11Department of Neurology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China; 2Department of Neurology, Jinshan ...
Song L,Yuan W, Wu N, Hong X, Chen Y, Yang X, Liu Z   +5 more
doaj  

Through the body into the brain: The pathway of Levodopa in Parkinson's disease

reservedLa Levodopa rappresenta da sempre il trattamento farmacologico di base adoperato al fine di gestire e contrastare la progressione sintomatica della malattia di Parkinson.
D'AUGUSTA PERNA, CHIARA
core  

Preclinical models of levodopa-induced dyskinesia

, 2014
L -DOPA-induced dyskinesia (LID) represents one of the major limitations in the current pharmacotherapy of Parkinson's disease (PD) and affects the majority of PD patients.
Francardo, Veronica,, Cenci, M. Angela,, Lund University.   +2 more
core   +1 more source

Impact of Istradefylline on Levodopa Dose Escalation in Parkinson’s Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study

Neurology and Therapy
Introduction A higher levodopa dose is a risk factor for motor complications in Parkinson’s disease (PD). Istradefylline (IST) is used as adjunctive treatment to levodopa in PD patients with off episodes, but its impact on levodopa dose titration remains
Taku Hatano, Renpei Sengoku, Hiroshi Nagayama, Naotake Yanagisawa, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Kenichi Kaida, Ryoko Ihara, Kazutomi Kanemaru, Osamu Kano   +28 more
doaj   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

New levodopa therapeutic strategies

, 2016
During its almost half-century of use for treating Parkinson\u27s disease, levodopa therapy has permitted most patients to reverse much of this disorder\u27s symptomatology.
LeWitt, Peter A
core  

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination

, 2005
Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa.
Castro, A, Hernandez, B, Obeso, E J, Luquin, M R, Tolosa, E S, Vaamonde, J, Jenner, P, Pavon, N, Grandas, F, Marin, C, Valldeoriola, F, Linazasoro, G, Stochi, F, Macias, R, Gimenez-Roldan, S, Alvarez, L, Rodriguez-Oroz, M C, Rodriguez, M   +17 more
core  

Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone

, 2017
Background: Levodopa bioavailability is enhanced by adding entacapone. However, the optimal dose of levodopa while transitioning to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) during the wearing-off period is unclear.
이필휴, 손영호
core   +1 more source